Executive Team

James Duckenfield

James Duckenfield

James is CEO of Glass Pharms.

Glass Pharms cultivates cannabis for the UK medicines market. Fully Home Office and MHRA compliant, they hold the first UK commercial licence to grow High-THC cannabis flower for lawful third parties to produce Cannabis Based Products for Medical Use in Humans (CBPMs).

James has over 20 years of general management experience in a broad range of companies; and has founded, grown and exited several firms. He takes a balanced approach to his leadership of Glass Pharms, combining the latest scientific research with the practicalities of the latest protected agricultural practices.

James believes that Glass Pharms will be a key asset for the UK’s medicine security.


Arthur Wakeley

Arthur Wakeley

Arthur is Managing Director of Celadon Pharmaceuticals.

Celadon Pharmaceuticals is a UK leader focused on the research, cultivation, manufacture and supply of breakthrough cannabis-based medicines. The firm is listed on the London Stock Exchange (AIM), has a 100,000 sq ft manufacturing facility in the West Midlands with indoor hydroponic cultivation and has rolled out clinical trial programmes in chronic pain and autism.

Arthur has wide ranging experience across strategy, business-building and corporate finance. He worked previously at the world’s leading strategy consultant firm McKinsey & Company, and within M&A investment banking at Lazard.

Arthur believes that Celadon is leading the way in building the exciting life sciences sector of breakthrough cannabis-based medicines, and has seen how transformative these medicines can be for patients on Celadon’s own chronic pain clinical trial.

Dr Sebastian Vaughan

Dr Sebastian Vaughan

Sebastian is CEO of Phytome Life Sciences.

Phytome Life Sciences is an integrated science, technology and commercialisation platform that identifies, develops and accelerates disease-targeted drug discovery and new therapeutics to market.

Sebastian was the creator of the Phytome vision and has over 20 years’ experience in pre-clinical drug development, technology and consultancy.

Sebastian believes that Phytome will deliver the required research capabilities and life sciences investment opportunities to radically accelerate safe and effective new medicines to those in need.